相关实验视频

Updated: Jun 5, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

心脏重编程和Gata4过度表达可减少纤维化,改善心力衰竭中的透气功能障碍

Yu Yamada¹, Taketaro Sadahiro², Koji Nakano¹

¹Department of Cardiology (Y.Y., K.N., S.H., Y.A., T.A., R.F.), University of Tsukuba, Japan.

|December 14, 2024

概括

使用心脏纤维细胞 (CFs) 的 Gata4 过度表达进行心脏重编程,有望治疗心脏衰竭的保留射出分数 (HFpEF). 这种方法可以减少纤维化,改善腹功能,为HFpEF提供潜在的新疗法.

科学领域:

心脏病学
复原医学
纤维化研究

背景情况:

心脏衰竭与保存的喷射分数 (HFpEF) 是一种严重的健康问题,其特征是心脏纤维化和心脏扩张功能障碍.
在HFpEF中驱动纤维化的机制尚未完全理解,并且缺乏有效的向治疗.
心脏重编程,涉及Mef2c/Gata4/Tbx5/Hand2 (MGTH) 的过度表达,已显示可能导致心肌梗塞,但其对HFpEF的有效性尚不清楚.

研究的目的:

在HFpEF小鼠模型中研究心脏重编程的有效性.
阐明HFpEF心脏纤维化背后的机制.
在HFpEF中评估个别重编程因子的治疗潜力,特别是Gata4.

主要方法:

使用高脂肪饮食和氧化合成酶抑制的已建立的HFpEF模型小鼠.
使用转基因小鼠对心脏纤维细胞 (CFs) 过度表达,用于重新编程和谱系追踪.
使用大量RNA测序,单细胞RNA测序和空间转录组学来分析纤维化机制和重编程效应.
研究了单个重编程因素对人类CF的影响.

主要成果:

在HFpEF小鼠中,MGTH过度表达改善了腹功能障碍,心脏缩,纤维化,炎症和毛细血管损失.
心脏重编程将大约1%的CF转化为诱导心肌细胞,高调心脏收缩基因,并抑制胎儿基因程序和亲肌特征.
单细胞和空间转录组显示MGTH逆转了导致间歇性纤维化和周围血管纤维化的不同CF的变化.
通过抑制CF激活而没有诱导新的心肌细胞,单独过度表达Gata4可降低纤维化和改善腹功能,同时也可以抑制人类CF的益肌特征.

结论:

在心脏纤维细胞 (CFs) 中,Gata4的过度表达为HFpEF提供了有前途的治疗策略.
通过Gata4进行重新编程,有效地抑制心脏纤维化,改善HFpEF的扩张功能障碍.
通过Gata4准CF激活为治疗HFpEF提供了潜在的新途径.

关键词:

心脏纤维细胞纤维化心脏衰竭单细胞RNA测序空间转录学

更多相关视频

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5

Published on: November 13, 2015

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...